193 related articles for article (PubMed ID: 38630476)
1. Treatment Failure and Long-Term Prescription Risk for Guideline-Recommended Hypnotics in Japan.
Takeshima M; Yoshizawa K; Ogasawara M; Kudo M; Itoh Y; Ayabe N; Mishima K
JAMA Netw Open; 2024 Apr; 7(4):e246865. PubMed ID: 38630476
[TBL] [Abstract][Full Text] [Related]
2. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea.
Mason M; Cates CJ; Smith I
Cochrane Database Syst Rev; 2015 Jul; (7):CD011090. PubMed ID: 26171909
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F; D'Alò GL; Ostinelli EG; Ciabattini M; Di Franco V; Watanabe N; Kurtulmus A; Tomlinson A; Mitrova Z; Foti F; Del Giovane C; Quested DJ; Cowen PJ; Barbui C; Amato L; Efthimiou O; Cipriani A
Lancet; 2022 Jul; 400(10347):170-184. PubMed ID: 35843245
[TBL] [Abstract][Full Text] [Related]
4. Patterns of hypnotic prescribing for residual insomnia and recurrence of major depressive disorder: a retrospective cohort study using a Japanese health insurance claims database.
Yamato K; Inada K; Enomoto M; Marumoto T; Takeshima M; Mishima K
BMC Psychiatry; 2021 Jan; 21(1):40. PubMed ID: 33441086
[TBL] [Abstract][Full Text] [Related]
5. Eszopiclone for insomnia.
Rösner S; Englbrecht C; Wehrle R; Hajak G; Soyka M
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010703. PubMed ID: 30303519
[TBL] [Abstract][Full Text] [Related]
6. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.
Sateia MJ; Buysse DJ; Krystal AD; Neubauer DN; Heald JL
J Clin Sleep Med; 2017 Feb; 13(2):307-349. PubMed ID: 27998379
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological interventions for the treatment of insomnia: quantitative comparison of drug efficacy.
Zheng X; He Y; Yin F; Liu H; Li Y; Zheng Q; Li L
Sleep Med; 2020 Aug; 72():41-49. PubMed ID: 32544795
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nonbenzodiazepine hypnotics for chronic insomnia in patients with bipolar disorder.
Schaffer CB; Schaffer LC; Miller AR; Hang E; Nordahl TE
J Affect Disord; 2011 Feb; 128(3):305-8. PubMed ID: 20701978
[TBL] [Abstract][Full Text] [Related]
9. Hypnotic prescription trends and patterns for the treatment of insomnia in Japan: analysis of a nationwide Japanese claims database.
Okuda S; Qureshi ZP; Yanagida Y; Ito C; Homma Y; Tokita S
BMC Psychiatry; 2023 Apr; 23(1):278. PubMed ID: 37081408
[TBL] [Abstract][Full Text] [Related]
10. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.
Najib J
Clin Ther; 2006 Apr; 28(4):491-516. PubMed ID: 16750462
[TBL] [Abstract][Full Text] [Related]
11. Greater incidence of depression with hypnotic use than with placebo.
Kripke DF
BMC Psychiatry; 2007 Aug; 7():42. PubMed ID: 17711589
[TBL] [Abstract][Full Text] [Related]
12. Risk of psychiatric disorders in patients with chronic insomnia and sedative-hypnotic prescription: a nationwide population-based follow-up study.
Chung KH; Li CY; Kuo SY; Sithole T; Liu WW; Chung MH
J Clin Sleep Med; 2015 Apr; 11(5):543-51. PubMed ID: 25766696
[TBL] [Abstract][Full Text] [Related]
13. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations.
Walsh JK; Krystal AD; Amato DA; Rubens R; Caron J; Wessel TC; Schaefer K; Roach J; Wallenstein G; Roth T
Sleep; 2007 Aug; 30(8):959-68. PubMed ID: 17702264
[TBL] [Abstract][Full Text] [Related]
14. Review of Safety and Efficacy of Sleep Medicines in Older Adults.
Schroeck JL; Ford J; Conway EL; Kurtzhalts KE; Gee ME; Vollmer KA; Mergenhagen KA
Clin Ther; 2016 Nov; 38(11):2340-2372. PubMed ID: 27751669
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of hypnotics in young and middle-aged adults with insomnia: a systematic review and network meta-analysis.
Hasan F; Lee HC; Chen PY; Wang YH; Yuliana LT; Romadlon DS; Tu YK; Chiu HY
Sleep Breath; 2023 Oct; 27(5):2021-2030. PubMed ID: 36928548
[TBL] [Abstract][Full Text] [Related]
16. Residual effects of low dose of suvorexant, zolpidem, and ramelteon in healthy elderly subjects: A randomized double-blind study.
Uemura SI; Imanishi A; Terui Y; Park I; Satake M; Han G; Shioya T; Kanbayashi T; Nishino S
Neuropsychopharmacol Rep; 2022 Sep; 42(3):288-298. PubMed ID: 35748642
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study.
Ozone M; Hirota S; Ariyoshi Y; Hayashida K; Ikegami A; Habukawa M; Ohshima H; Harada D; Hiejima H; Kotorii N; Murotani K; Taninaga T; Uchimura N
Adv Ther; 2024 Apr; 41(4):1728-1745. PubMed ID: 38460107
[TBL] [Abstract][Full Text] [Related]
18. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder.
Pollack M; Kinrys G; Krystal A; McCall WV; Roth T; Schaefer K; Rubens R; Roach J; Huang H; Krishnan R
Arch Gen Psychiatry; 2008 May; 65(5):551-62. PubMed ID: 18458207
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression.
Krystal A; Fava M; Rubens R; Wessel T; Caron J; Wilson P; Roth T; McCall WV
J Clin Sleep Med; 2007 Feb; 3(1):48-55. PubMed ID: 17557453
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians.
Wilt TJ; MacDonald R; Brasure M; Olson CM; Carlyle M; Fuchs E; Khawaja IS; Diem S; Koffel E; Ouellette J; Butler M; Kane RL
Ann Intern Med; 2016 Jul; 165(2):103-12. PubMed ID: 27136278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
